Gerresheimer Kauft Pharmaglassparte von US-Hersteller
Gerresheimer is one of the leading manufacturers of pharma glass in the US and over a number of years has pushed ahead to achieve further business expansion through targeted acquisitions in this attractive market.
30/03/07 The Gerresheimer Group in Düsseldorf has agreed to acquire the pharma-glass operations of the US company Comar Inc. in Vineland (New Jersey). Closure of the deal is to take place at the end of March. Gerresheimer thereby consistently continues its expansion in the target market of pharma/life-science. In this highly specialised market, Gerresheimer ranks among the leading international suppliers of both glass and plastic products. Comar uses tubular glass to produce high-quality pharmaceutical vials and system components for pharmaceutics, diagnostics and analytical systems.
Gerresheimer is one of the leading manufacturers of pharma glass in the US and over a number of years has pushed ahead to achieve further business expansion through targeted acquisitions in this attractive market. Gerresheimer now has eight production plants in North America to supply the dynamic pharma/life-science business. “With highly-developed production technologies and an outstanding product range, the Glass Division of Comar ideally complements the Gerresheimer product portfolio,” says Dr. Axel Herberg, President and CEO of the Gerresheimer Group.
The Comar Glass Division has been firmly established in the American market for almost sixty years. With around 200 employees, up-to-date technologies and a top-quality product range, the company is highly regarded by its customers. The product range of the pharma-glass and diagnostics business taken over by Gerresheimer comprises a wide variety of pharmaceutical vials and sophisticated glass components for diagnostic and analytical systems. Comar sales in the pharma glass sector totalled around US$24m in 2006.
This acquisition once again highlights Gerresheimer’s dynamic development in the global high-growth target markets across the pharma/life-sciences sector. Just at the beginning of this year the Group purchased Wilden AG, thereby advancing to become one of the leading European suppliers of plastic-based pharmaceutical systems. In 2006 Gerresheimer also focussed on entry into the Chinese market: through numerous acquisitions in this fast-growing market region Gerresheimer secured a leading role as a supplier of products for the pharma/life-science sector. “Many of our customers are global players,” Herberg explains. “We can also supply them globally thanks to our worldwide facilities structure.” Gerresheimer currently has 32 production plants in Europe, America and Asia with 8,500 employees, and achieves sales of almost a billion euros.
